Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration

Table 2

Predictors of visual acuity score change and central retinal thickness change from baseline at 6 months.

Baseline characteristics	VA score change					CRT change (𝜇m)
	Letters			≥15 letters gain		𝑁	Median	𝑃^∗
	𝑁	Mean ± SD	𝑃	𝑛 (%)	𝑃
Age (years)
50–59	26	13.4±10.9	0.227	12 (46.2)	0.393	22	−47.0	0.504
60–69	43	9.9±15.1		13 (30.2)		42	−130.0
70–79	62	6.8±14.2		17 (27.4)		58	−77.5
≥80	13	10.0±12.2		4 (30.8)		10	−128.5
Gender
Male	95	9.1±14.7	0.928	31 (32.6)	0.805	86	−64.0	0.052
Female	49	9.3±12.2		15 (30.6)		46	−122.0
Smoking
No	77	9.3±14.3	0.996	26 (33.8)	0.659	72	−106.5	0.047
Yes	66	9.3±13.5		20 (30.3)		59	−56.0
Lesion type
Occult only	57	7.8±10.6	0.832*	13 (22.8)	0.104	55	−67.0	0.352
Minimally classic	21	11.1±18.8		10 (47.6)		20	−117.0
Predominantly classic	49	8.4±15.2		15 (30.6)		47	−82.0
Treatment regimen			0.035		0.626			0.492
A	74	11.6±12.6		25 (33.8)		65	−103.0
B	70	6.7±14.8		21 (30.0)		67	−56.0

CRT: central retinal thickness; SD: standard deviation; VA: visual acuity.
*Nonparametric testing.